Kiora Pharmaceuticals, Inc. (KPRX)
2.03
-0.12
(-5.58%)
USD |
NASDAQ |
Dec 05, 16:00
2.04
+0.01
(+0.49%)
After-Hours: 07:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.466M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -41.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.3332 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.018 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.93% |
Profile
| Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA. |
| URL | http://www.kiorapharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA. |
| URL | http://www.kiorapharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |